At the 2023 SNO Annual Meeting, Wayshine Biopharm presented the latest data on its fourth-generation EGFR inhibitor, WSD0922-FU, for the treatment of patients with osimertinib-resistant non-small cell lung cancer (NSCLC) and CNS metastases.